Drugs / TAS3681
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02566772 | Mar 2016 → Aug 2022 | prostate carcinoma | Taiho Oncology, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAS3681 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02566772 ↗ |
| Route | Oral | “administered orally” NCT02566772 ↗ |